In compliance with section 17(b) of the Securities Act, we are disclosing that OKYO Pharma Limited (NASDAQ: OKYO) is a client of TraDigital Marketing Group, Inc. OKYO Pharma Limited has a 3 month agreement in place, dated February 1, 2023 – April 30, 2024 to compensate TraDigital Marketing Group, Inc. a cash retainer of three hundred ninety thousand dollars ($390,000) paid as follows: a monthly cash fee of ten thousand dollars ($10,000) for investor relations services, plus three hundred sixty thousand dollars ($360,0000) for publicly disseminating information about OKYO Pharma Limited via website, email, and SMS. OKYO Pharma Limited has paid TraDigital Marketing Group, LLC a one-time stock fee of sixty-seven thousand shares of ordinary stock, restricted under Rule 144, for TraDigital Marketing Group, Inc., investor awareness and digital marketing services. The stock is eligible for sale on 08/01/2023. It is TraDigital’s intention to sell all of our shares once the restriction is lifted on 08/01/2023.
Investor awareness and investor relations services and programs are designed to help small-cap companies communicate their investment characteristics. TraDigital Marketing Group, Inc., investor awareness and advisory services include multimedia marketing and other awareness services.